INDP
NASDAQ · Biotechnology
Indaptus Therapeutics Inc
$3.15
-0.06 (-1.87%)
Open$3.15
Previous Close$3.21
Day High$3.20
Day Low$3.01
52W High$5.96
52W Low$0.92
Volume—
Avg Volume220.1K
Market Cap509.89M
P/E Ratio—
EPS$-7.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,194.3% upside
Current
$3.15
$3.15
Target
$40.77
$40.77
$30.54
$40.77 avg
$54.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.62M | 1.61M |
| Net Income | -161,760 | -172,924 | -142,728 |
| Profit Margin | -9.5% | -10.7% | -8.9% |
| EBITDA | -256,082 | -275,942 | -257,647 |
| Free Cash Flow | -132,527 | -99,336 | -105,630 |
| Rev Growth | +0.4% | +1.6% | -5.5% |
| Debt/Equity | 0.26 | 0.25 | 0.24 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |